Asarina Pharma AB (publ) (STO:ASAP)
Sweden
· Delayed Price · Currency is SEK 0.0280
-0.0126 (-31.03%)
Inactive · Last trade price
on Oct 1, 2024
Asarina Pharma AB Company Description
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products.
Its flagship product is Sepranolone, which is used for the treatment of menstrual migraine and Tourette syndrome.
The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016.
Asarina Pharma AB (publ) was incorporated in 2005 and is based in Solna, Sweden.
Asarina Pharma AB (publ)
| Country | Sweden |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Peter Nordkild |
Contact Details
Address: Karolinska Institutet Science Park Solna | |
| Phone | 46 8 52 48 44 82 |
Stock Details
| Ticker Symbol | ASAP |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0011641794 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Nordkild M.D. | Chief Executive Officer and Chief Medical Officer |
| Jakob Dynnes Hansen M.Sc., MBA | Chief Financial Officer |
| Torbjörn Bäckström M.D., Ph.D. | Chairman of Scientific Advisory Board |
| Mark DuBois | Communications Manager |
| Otto Skolling M.Sc | Chief Business Officer |